Additionally, ACER2 levels show a negative correlation with several well-characterized immune checkpoint inhibitors, which may hinder the re-activation of tumor-specific cytotoxic T lymphocytes responsible for targeting and eliminating cancer cells (92, 93). This evidence concerns the gene ACER2 and neoplasm.